Skip to main content
TipRanks
Go Ultimate75% OFF

Mesoblast Limited (LWB) Stock Price & Analysis

4 Followers

LWB Stock Chart & Stats

€1.13-€0.04(-3.50%)
At close: 5:30 PM GMT+1
€1.3€1.4€1.5Aug 26Sep 7Sep 14Oct 1Oct 15Nov 3
Day’s Range
EUR 1.13 - EUR 1.13
52-Week Range
EUR 1.06 - EUR 1.71
Previous Close
EUR 1.17
Volume
N/A
Average Volume (3M)
243
Market Cap
EUR 1.50B
Enterprise Value
EUR 3.52B
Total Cash (Recent Filing)
EUR 47.39M
Total Debt (Recent Filing)
EUR 127.33M
Price to Earnings (P/E)
―
Beta
0.98
Next Earnings
Mar 04, 2027 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Ryoncil Commercial Traction

Ryoncil has established a meaningful commercial base, supported by rapid treatment-center onboarding and broad payer access. Management’s FY2026 revenue guidance indicates further near-term growth, which could improve revenue visibility and enable operating scale as adoption expands.

High Gross Margin

The exceptionally high reported gross margin gives each incremental Ryoncil sale substantial contribution potential after product costs. If commercial investment becomes more efficient as the launch matures, this product economics could support future margin expansion and stronger earnings quality.

Advanced Clinical Pipeline

Mesoblast has multiple advanced programs with defined clinical and regulatory milestones, rather than relying solely on early research. Revascor and rexlemestrocel-L provide potential future indications and product opportunities that could broaden the company’s commercial platform over time.

Bears Say

Persistent Losses And Cash Burn

The company remains dependent on funding while operating cash flow and free cash flow are negative. Continued losses reduce financial flexibility and mean commercial growth must eventually outpace development and operating costs for Mesoblast to become self-sustaining.

Ryoncil Revenue Concentration

Near-term performance is highly dependent on one recently launched product, making revenue growth sensitive to Ryoncil’s adoption and execution. Until other programs generate commercial revenue, this concentration limits diversification and leaves the growth profile exposed to product-specific outcomes.

Elevated Development And Launch Spending

Substantially higher R&D and commercial spending is funding pipeline advancement and the Ryoncil launch, but it also prolongs losses and cash consumption. Mesoblast must convert these investments into durable product growth and approvals before they can translate into sustainable profitability.

Mesoblast Limited News

LWB FAQ

What was Mesoblast Limited’s price range in the past 12 months?
Mesoblast Limited lowest stock price was €1.06 and its highest was €1.71 in the past 12 months.
What is Mesoblast Limited’s market cap?
Mesoblast Limited’s market cap is €1.50B.
When is Mesoblast Limited’s upcoming earnings report date?
Mesoblast Limited’s next earnings report is estimated for May 28, 2025 (not yet confirmed), which is 539 days ago.
How were Mesoblast Limited’s earnings last quarter?
Mesoblast Limited released its earnings results on Feb 27, 2026. The company reported -€0.028 earnings per share for the quarter, missing the consensus estimate of -€0.006 by -€0.022.
Is Mesoblast Limited overvalued?
According to Wall Street analysts Mesoblast Limited’s price is currently Undervalued.
Does Mesoblast Limited pay dividends?
Mesoblast Limited does not currently pay dividends.
What is Mesoblast Limited’s EPS estimate?
Mesoblast Limited’s EPS estimate is -0.01.
How many shares outstanding does Mesoblast Limited have?
Mesoblast Limited has 1,301,298,100 shares outstanding.
What happened to Mesoblast Limited’s price movement after its last earnings report?
Mesoblast Limited reported an EPS of -€0.028 in its last earnings report, missing expectations of -€0.006. Following the earnings report the stock price went down -7.752%.
Which hedge fund is a major shareholder of Mesoblast Limited?
Currently, no hedge funds are holding shares in DE:LWB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology